Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
0 hedge funds and large institutions have $0 invested in Opiant Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 36 closing their positions.
100% less funds holding
Funds holding: 37 → 0 (-37)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $41.2M → $0 (-$41.2M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 36
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$8.6M |
| 2 |
ACA
Apis Capital Advisors
New York
|
-$4.34M |
| 3 |
Morgan Stanley
New York
|
-$4.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.87M |
| 5 |
Renaissance Technologies
New York
|
-$2.97M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Mariner
Overland Park,
Kansas
| – | -$214K | -10,550 | Closed |
|
|
GI
27
GAMCO Investors
Greenwich,
Connecticut
| – | -$203K | -10,000 | Closed |
|
28
Osaic Holdings
Scottsdale,
Arizona
| – | -$111K | -5,500 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$56.8K | -2,802 | Closed |
|
|
LC
30
Lindbrook Capital
Calabasas,
California
| – | -$40.6K | -2,000 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$24K | -1,200 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$21.7K | -1,070 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$15K | -744 | Closed |
|
|
SWM
34
Spire Wealth Management
Mclean,
Virginia
| – | -$10K | -500 | Closed |
|
|
BWP
35
Baldwin Wealth Partners
Marion,
Massachusetts
| – | -$6.08K | -300 | Closed |
|
|
FDCDDQ
36
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$3.65K | -180 | Closed |
|
OPNT Hedge Fund Activity: Q1 2023 in Review
0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2023, worth a combined $0 — down 100% from $41.2M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of OPNT and 0 opened new positions — a net loss of 36 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Western Standard LLC, exiting entirely with an estimated $8.6M sold.
- 0 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $0 of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 36 closed out, a net change of -36 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Western Standard LLC, an estimated $8.6M sold.
Based on aggregated 13F filings for Q1 2023.